1. Home
  2. RYTM vs TXG Comparison

RYTM vs TXG Comparison

Compare RYTM & TXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rhythm Pharmaceuticals Inc.

RYTM

Rhythm Pharmaceuticals Inc.

HOLD

Current Price

$115.63

Market Cap

5.8B

Sector

Health Care

ML Signal

HOLD

Logo 10x Genomics Inc.

TXG

10x Genomics Inc.

HOLD

Current Price

$52.03

Market Cap

6.0B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
RYTM
TXG
Founded
2008
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Laboratory Analytical Instruments
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
5.8B
6.0B
IPO Year
2017
2019

Fundamental Metrics

Financial Performance
Metric
RYTM
TXG
Price
$115.63
$52.03
Analyst Decision
Strong Buy
Hold
Analyst Count
14
15
Target Price
$131.14
$20.25
AVG Volume (30 Days)
640.7K
2.8M
Earning Date
05-05-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
28.34
76.97
EPS
N/A
N/A
Revenue
N/A
$245,893,000.00
Revenue This Year
$55.34
N/A
Revenue Next Year
$86.06
$7.33
P/E Ratio
N/A
N/A
Revenue Growth
N/A
68.06
52 Week Low
$74.50
$11.17
52 Week High
$122.20
$50.34

Technical Indicators

Market Signals
Indicator
RYTM
TXG
Relative Strength Index (RSI) 60.52 55.55
Support Level $98.76 $16.11
Resistance Level $113.03 N/A
Average True Range (ATR) 4.84 2.78
MACD 0.15 -0.55
Stochastic Oscillator 98.64 43.64

Price Performance

Historical Comparison
RYTM
TXG

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.

About TXG 10x Genomics Inc.

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).

Share on Social Networks: